We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ENTG:NASDAQEntegris, Inc. Analysis

Data as of 2026-08-01 - not real-time

$119.05

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Entegris is trading at $119.05, well below its 20‑day SMA of $133.15 and 50‑day SMA of $143.34, suggesting short‑term weakness, yet the 200‑day SMA sits at $119.20, providing a long‑term anchor. The RSI of 39.9 points to a near‑oversold condition, while a bearish MACD histogram reinforces downside pressure. However, the forward EPS estimate of $4.70 implies earnings could more than double the trailing $1.76, and analysts have raised price targets to $166–$180, indicating strong growth expectations. The stock’s PE of 67.6 dwarfs the industry average of 32.8 and the DCF fair value of $24.6, flagging a substantial valuation premium. A modest dividend of $0.10 per quarter (0.34% yield) with a 23% payout ratio appears sustainable given positive free cash flow, but the debt‑to‑equity ratio of 92.8% raises leverage concerns. Volatility is extreme at 95% over 30 days and beta exceeds 3, reflecting heightened market sensitivity. Recent news of a dividend authorization and analyst upgrades have sparked a 4.5% price jump on higher‑than‑average volume, but the upcoming Q2 results could add further direction. Overall, the company sits at the intersection of strong secular demand for semiconductor materials and a stretched valuation, making the near‑term outlook mixed while the medium‑term upside remains compelling.
Investors should weigh the upside potential against the high beta, elevated volatility, and leverage. A cautious stance—holding or modest buying on dips—may be prudent until earnings clarity emerges, after which the longer‑term narrative of industry tailwinds could justify a higher allocation.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below short‑term moving averages and bearish MACD
  • Near‑oversold RSI with elevated volatility
  • Upcoming Q2 earnings release

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong forward earnings growth and analyst target lifts
  • Sustainable dividend and positive free cash flow
  • Secular demand for semiconductor materials

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Significant valuation premium versus DCF
  • High leverage and beta increasing systematic risk
  • Long‑term industry tailwinds in advanced nano‑chip manufacturing

Key Metrics & Analysis

Financial Health

Revenue Growth5.00%
Profit Margin8.18%
P/E Ratio67.6
ROE6.79%
ROA3.75%
Debt/Equity92.80
P/B Ratio4.5
Op. Cash Flow$738.0M
Free Cash Flow$445.1M
Industry P/E32.8

Technical Analysis

TrendNeutral
RSI40.0
Support$106.91
Resistance$155.08
MA 20$133.15
MA 50$143.34
MA 200$119.20
MACDBearish
VolumeStable
Fear & Greed Index92.88

Valuation

Fair Value$24.62
Target Price$166.00
Upside/Downside39.44%
GradeOvervalued
TypeGrowth
Dividend Yield0.34%

Risk Assessment

Beta3.17
Volatility95.11%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.